think of Vivus ( VVUS ), Arena Pharmaceuticals ( ARNA ), and Orexigen ( OREX ). These three companies have been the center of attention ..... two already have products on the market, and the third, Orexigen , is likely to see its anti-obesity drug approved this Fall
the equity to appreciate. The frustrations seem to have come to a head following the combination of a delay for competitor Orexigen combined with a 23% uptick in week over week prescription sales numbers last week. Investors seem to feel that these two
investors in Arena Pharmaceuticals ( ARNA ). The sales of Belviq took an anticipated dip with last week's numbers, competitor Orexigen ( OREX ) saw its application for approval of Contrave delayed until September, Arena's CEO spoke on CNBC, and this weeks numbers
Orexigen Therapeutics ( OREX ) Orexigen Receives Three Month Extension of FDA NB32 Review June 11, 2014 ..... Mathew Andrews - Wells Fargo Presentation Operator Welcome to the Orexigen Conference Call. My name is Joan and I will be your operator
June 11 (Reuters) - Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed a decision on the marketing application for its obesity drug, contrave, by three months, sending the...
By Spencer Osborne : Orexigen ( OREX ) announced this morning that an FDA decision on approval of the ..... approval were in the equity for the trade. Two months ago I labeled Orexigen as a buying opportunity with the stock near $5. At that point
The FDA extends its review of Orexigen Therapeutics ' ( OREX ) resubmitted NDA for NB32 , the company's weight loss ..... agreement on the remaining post-marketing obligation." OREX shares are down 11% premarket on robust volume. Post
June 11 (Reuters) - Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed its decision on the marketing application of its obesity drug, contrave, by three months, sending its...
By Spencer Osborne : Orexigen ( OREX ) is just a day away from receiving ..... VVUS ). Leading up to this date, Orexigen has seen a nice run in its stock ..... around $7.00. At this point, Orexigen longs may not appreciate what I have
dots for you. This will be one of those occasions. This Wednesday, the FDA will likely make a determination about the Orexigen ( OREX ) entry (Contrave) into the anti-obesity space. This is both good news and bad news for investors in Arena Pharmaceuticals